Table 2.
Summary of studies on CC biomarkers discovered through transcriptomics
| Article type | Population | Study period | Sample size | Source of sample | Platform/ assay technique | Stage of research | Association to CC | Significance | References |
|---|---|---|---|---|---|---|---|---|---|
| Review article | NA | 2011–2020 | NA | NA | High throughput sequencing technology | NA | Prognostic marker, CC metastasis |
Dysregulation of ncRNAs miRNAs, miR-21, miR-221-3p, miR-199b-5p, miR-29a, miR-543, miR-106b, miR-519d, miR-218-5p, miR-200b, miR-484, miR-145, miR-211, miR-183, miR-124 and miR-221-3p lncRNAs, MALAT1, EBIC, TUG1, CTS, HOTAIR, Xist, 799, XLOC_006390, TTN-AS1, ZNF667-AS1, DANCR, PVT1, GA5-AS1, DGCR5 and ANRIL circRNAs, circ-0000745, circ-000284, circ-NRIP1, circ-0003204 and circUBAP2 |
[50] |
| Systematic review | NA | 2010–2017 | 24 studies | Tissue |
RT-PCR qPCR Microarray |
NA |
Risk/ susceptible marker Prognostic biomarker |
Downregulation of miR-29a and upregulation of miR-21 | [53] |
| Research article | Hong Kong | 2006–2013 |
582 cases 145 controls |
Tissue | qPCR | Multiphase case–control study | Diagnostic marker | Upregulation of miR‐20a, miR‐92a, miR‐141, miR‐183*, miR‐210 and miR‐944 | [55] |
| Research article | China | 2009–2018 |
165 cervical adenocarcinoma cases 81 normal controls |
Tissue | RT-qPCR | Case control study | Diagnostic marker |
Upregulation of VIL1, HNF1A-AS1, MIR194-2HG, SSTR5-AS1, miR-192-5p, and miR-194-5p in adenocarcinoma Combined miR-192-5p, HNF1A-AS1, and VIL1 |
[56] |
| Review article | NA | 2007–2016 | NA | NA | NA | NA |
Diagnostic marker Prognostic marker Therapeutic marker |
HOTAIR, MALAT1, CCAT2, SPRY4-IT1, RSU1P2, CCHE1, lncRNA-EBIC and PVT1 | [57] |
| Research article | China | 2016–2017 | 29 CC tissues and peritumoral tissues | Tissue |
Microarray RT-qPCR |
Case control study In vitro (cell lines) |
Prognostic marker | Upregulation of lncRNA-AK001903 | [59] |
| Research article | China | 2012–2021 | 23 pairs of CC and adjacent tissues | Tissue |
Microarray qPCR Western blot |
Case control study | Prognostic marker | Elevated PCBP1-AS1 | [60] |
| Research article | NA | NA | 292 CC specimens | NA |
iClusterPlus DESeq2 GSEA WGCNA GSVA |
Case control study | Prognostic marker | lncRNAs-based signature consisted of 8 lncRNAs, namely RUSC1-AS1, LINC01990, LINC01411, LINC02099, H19, LINC00452, ADPGK-AS1, C1QTNF1-AS1 | [61] |
| Review article | NA | 2003–2019 | NA | NA | NA | NA |
Diagnostic marker Therapeutic marker |
circRNAs in CC carcinogenesis and progression | [63] |
| Research article | China | 2015–2017 |
352 CC cases 204 CIN cases 227 healthy controls |
Tissue |
RT-PCR Western blot |
Case control study In vitro (cell lines) |
Diagnostic marker Prognostic marker |
Elevated CDR1 | [68] |
| Research article | NA | NA |
87 CC samples 44 normal controls |
NA |
Differential expression analysis using t-test Differential co-expression analysis using Fisher Z- test |
Case control study |
Risk/susceptible marker Therapeutic marker |
Epidermis development-associated gene set around ZNF135 | [65] |